Genomic Therapy Matching in Rare and Refractory Cancers - PubMed

8 hours ago

Genomic therapy matching in rare and refractory cancers was studied using a tiered, evidence-based framework.
Patients with tier 1-3A biomarkers receiving matched therapy had longer median overall survival (21.2 months) compared to unmatched therapy (12.8 months).
No survival benefit was observed for therapies matched to investigational evidence (tiers 3B/4) compared to unmatched therapy.
Therapies repurposed from other cancer types based solely on biomarkers (tier 3B) did not improve survival.
The findings support prioritizing genomically guided therapies backed by prospective clinical trial evidence.

Hasty Briefsbeta